Prospective Observational

Slides:

Advertisements

Similar presentations

Methods n Insert your text here. You can place your organizations logos on either side of the title of the poster. Insert your text here. n Remember to.

Advertisements

YOUR DISCLOSURE STATEMENT Of particular note this year is a rule change by ACCME regarding standards for commercial support, specifically: Standard 4.3:

How to Write a Scientific Paper Hann-Chorng Kuo Department of Urology Buddhist Tzu Chi General Hospital.

Review of a pharmacist discharge medication reconciliation program: characterization of medication discrepancies and prescriber follow up in patients with.

Title Name Institute. Background -1 (Main problem)

Evaluation of Patient Insulin Injection Technique in a University-Affiliated Outpatient Continuity Clinic Shelley King, Pharm. D. Candidate , Kathileen.

Compliance with clinical practice guidelines for the treatment and optimization of therapy in heart failure patients in outpatient medicine clinics MaryAnn.

Evaluation of intravenous acetaminophen use in a large community hospital Andrew R. Mameli, Pharm.D. Candidate, Nicholas L. Massie, Pharm.D., Richard L.

Evaluating clinical pharmacist impact on diabetes control: outcomes on hemoglobin A1c Mark Amoo PharmD Candidate, Dalton Walsh PharmD Candidate, Kalyani.

Safety of Perioperative Aspirin Use in Pancreatic Surgery Andrea M Wolf, Jordan M Winter, Salil D Gabale, Eugene P Kennedy, Ernest L Rosato, Harish Lavu,

INTRODUCTION Evaluation of Outcomes in Patients Starting Antiretroviral Therapy During Hospitalization Leigh E. Efird, PharmD 1, Manish Patel, PharmD 1,

* Indicates p < 0.05 indicates p < 0.05 Evaluating Clinical Pharmacist Impact on Diabetes Control* Mary Ella Hill, Pharm. D. Candidate; Orijane Dalton,

Ｐｒｅｖｅｎｔｉｎｇ Surgical Site Infection in Older Patients after Spine Surgery Application and Efficacy of Nutrition Support Team Shunji Matsunaga, Hiroaki Koga,

Comparison of two cardiovascular risk assessment tools to determine appropriate use of aspirin as primary prevention for patients with type 2 diabetes.

Outcomes of Individualized Formative Assessments in the Pharmacy Skills Laboratory Tyler H. Gums, Pharm.D. & Erika L. Kleppinger, Pharm.D., BCPS, CDE Auburn.

Methods n Insert your text here. You can place your organizations logos on either side of the title of the poster. Insert your text here. n Remember to.

Methods n Insert your text here. You can place your organizations logos on either side of the title of the poster. Insert your text here. n Remember to.

Title Authors Introduction Text, text, text, text, text, text Background Information Text, text, text, text, text, text Observations Text, text, text,

Presentation Title Speaker Name. Conflict of Interest Disclosures for Speakers 1. I do not have any potential conflicts to disclose. 2. I wish to disclose.

Methods n Insert your text here. You can place your organizations logos on either side of the title of the poster. Insert your text here. n Remember to.

Baseline Characteristics of the Patients* - Part I The ONTARGET Investigators. N Engl J Med 2008 [Epub on Mar 31]

Consequences Of Non-Compliance To Osteoporosis Medication Among Osteoporotic Women Ankita Modi, Ph.D, M.D. 1, Jackson Tang, M.Sc. 2, Shuvayu Sen, Ph.D.

The Effects of Intravenous Acetaminophen Use on Robot-Assisted Pelvic Surgery Patients Nichole Witmyer, Pharm.D. St. Dominic Hospital Jackson, Mississippi.

Financial Interest Disclosure (over the past 24 months) Commercial Interest Relationship Company A advisory board, consultant, investigator Company B speaker.

Clinical Pharmacists' Recommendations in Critical Care Areas of an Egyptian Tertiary Care Hospital: Interventions Analysis and Effect on Direct Drug Cost.

Disclosure Statement These individuals have nothing to disclose concerning possible financial or personal relationships with commercial entities (or their.

Your Poster Title Here Abstract Methods Results Conclusion Objectives

YOUR DISCLOSURE STATEMENT

YOUR DISCLOSURE STATEMENT

Safety and efficacy of insulin guideline for controlling perioperative hyperglycemia Marwa Amer PharmD Candidate1, Mark Shelly MD2, Dianne Lee PharmD Candidate1,

The Names of the Authors Can Go Here

Insert Your Poster Title

Design of Clinical Trials

Utilizing the Candida Score to Identify Patients at Increased Risk for

Pre-program Medication Errors (Jan-Sep 2006; n=191)

Pre-program Medication Errors (Jan-Sep 2006; n=191)

The Names of the Authors Can Go Here

The Anatomy of a Scientific Article: IMRAD format

Your Very Long Two Line Poster Title Goes Here

Your Very Long Two Line Poster Title Goes Here

Research Rotation Part II

Insert Your Poster Title Here The Names of the Authors Can Go Here

Insert Your Poster Title

YOUR DISCLOSURE STATEMENT

The Names of the Authors Can Go Here

Disclosure Information 87th Annual Scientific Meeting Speaker’s Name Here I have the following financial relationships to disclose: (select those that.

Financial Interests or Relationships

Disclosure Information 89th Annual Scientific Meeting I have the following financial relationships to disclose: (select those that.

Authors Institution(s)

First and last name D E P T O F L First and last name A B R Y M

FIRST LAST Name Title of Session Title of Presentation.

The Names of the Authors Can Go Here

Pre-program Medication Errors (Jan-Sep 2006; n=191)

Pre-program Medication Errors (Jan-Sep 2006; n=191)

Disclosure of conflicts of interest – explanation

The Names of the Authors Can Go Here

Financial Interests or Relationships

Insert Your Poster Title Here The Names of the Authors Can Go Here

Disclosure Information 90th Annual Scientific Meeting I have the following financial relationships to disclose: (select those that.

Disclosure of conflicts of interest

Disclosure of conflicts of interest

The Names of the Authors Can Go Here

Pre-program Medication Errors (Jan-Sep 2006; n=191)

The Names of the Authors Can Go Here

Financial Disclosure Financial Interest / Affiliation

Suggested Slide Layout & Developing PowerPoint Slides

Declaration of Financial Interests or Relationships

Pre-program Medication Errors (Jan-Sep 2006; n=191)

YOUR DISCLOSURE STATEMENT

Pre-program Medication Errors (Jan-Sep 2006; n=191)

Presentation transcript:

Prospective Observational Title of study Principal Investigator Names Background Methods Data Collection INFO More info ADDITIONAL INFO INFO More info ADDITIONAL INFO Financial Implications: Hospitals with poorest performance in preventing hospital-acquired events, including VTE, are subject to a 1% reduction in their annual Medicare/Medicaid reimbursement5 Study setting: University of New Mexico Hospitals Study design: XX study Study groups: Cases: (XX patients) INFO Controls: (XX patients) Inclusion Criteria Patient Info XXX Data Analysis INFO More info ADDITIONAL INFO Case Control Prospective Observational Data Info Exclusion Criteria Patient Info XXX Expectations INFO More info ADDITIONAL INFO Detailed Information References Risk Definition Pre-op cessation Post-op resumption List references Objectives Primary Objective: XXX Secondary Objectives: XXX: Disclosure: Authors of this presentation have the following to disclose concerning possible financial or personal relationships with commercial entities that may have a direct or indirect interest in the subject matter of this presentation: Name – nothing to disclose More info from table XXX